New data from the HELIOS-B Phase 3 trial show Alnylam's AMVUTTRA (vutrisiran) provides sustained cardiovascular benefits in patients with ATTR-CM for up to 48 months. This includes a significant reduction in mortality and cardiovascular events. The findings reinforce vutrisiran's potential as a first-line treatment.
In Dubai, Hasan Ates Budak and Dior Medya deliver web and PR solutions for brands in…
Arnhem-based Deftpower has raised €12.5 million to grow its AI-powered EV charging platform, aiming to optimise…
Amsterdam-based Framer has raised €85.6 million in Series D funding, valuing the company at €1.7 billion.…
London-based LogisticsTech startup Synkka has raised a pre-Seed round to accelerate the rollout of its AI-powered…
UK startup Palmer Energy Technology Limited has acquired Oxford spin-out Brill Power in a deal supported…
Artificial Societies, a London-based startup building AI-driven synthetic persona simulations, has raised €4.5 million across pre-Seed…
Global e-commerce platform Temu is launching its “local-to-local” initiative in Turkey, opening its marketplace to local…
The partnership will establish a joint venture to develop and deploy Llama-based AI tools for Indian…
BlackRock CEO Larry Fink states the U.S. retirement model is outdated. He stresses the urgent need…
XTransfer‘s new PMI report for July 2025 reveals a significant trend. Chinese SMEs are increasingly looking…
Uncovered Fund and Monex Ventures have partnered to create a $20 million fund targeting early-stage startups…
Entrepreneur Riadh Omar is leveraging his journey from a waiter in Denmark to a Dubai-based fintech…
Once a £1.7B fashion titan, Superdry went private at a £6M valuation. Founder Julian Dunkerton is…
Former Viking Global CIO Ning Jin’s new hedge fund, Avantyr Capital, has filed its initial ADV,…
Lakestar, an early investor in Spotify and Revolut, has closed a $265M continuation fund. The vehicle,…
Aurasell, an AI-native CRM startup, has raised $30 million in a seed round to challenge legacy…